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Abstract
We live in the era of genomics and big data. Evaluating the impact on health of large-scale 
biological, social, and environmental data is an emerging challenge in the field of epidemiology. 
In the past 3 years, major discussions and plans for the future of epidemiology, including with 
several recommendations for actions to transform the field, have been launched by 2 institutes 
within the National Institutes of Health. In the present commentary, I briefly explore the themes of 
these recommendations and their effects on leadership, resources, cohort infrastructure, and 
training. Ongoing engagement within the epidemiology community is needed to determine how to 
shape the evolution of the field and what truly matters for changing population health. We also 
need to assess how to leverage existing epidemiology resources and develop new studies to 
improve human health. Readers are invited to examine these recommendations, consider others 
that might be important, and join in the conversation about the future of epidemiology.
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A recent blog post (1) summarized the results of multiyear strategic efforts and discussions 
on planning for the future of epidemiology conducted by 2 institutes within the National 
Institutes of Health, the National Cancer Institute and the National Heart, Lung, and Blood 
Institute. Although the 2 institutes had independent processes, they both arrived at somewhat 
comparable and overlapping lists of broad and specific recommendations for actions that fall 
into thematic areas: leadership, resources, epidemiology cohorts, methods and technologies, 
workforce development, data and knowledge integration, and impact evaluation (Table 1). 
The primary impetus behind these recommendations is to transform the field and its funding 
strategies at a time of big data science (2) and technological developments but also resource 
constraints (3). Given the continued importance of epidemiology as a foundational science 
for public health and clinical practice, we at the American Journal of Epidemiology seek to 
encourage an open dialogue and sharing of ideas with our readers about the future of the 
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field. We feel that these recommendations and related questions for discussion shown in 
Table 1 are worthy of further exploration by the community and are applicable beyond the 
subject areas of cardiovascular disease and cancer to the field of epidemiology as a whole.
The planning for the future of epidemiology by 2 institutes within the National Institutes of 
Health coincides with the launch of the Precision Medicine Initiative (4) in 2015. A major 
component of this initiative is the establishment of a large longitudinal epidemiology cohort 
of a million or more participants in whom genetic and environmental determinants of a wide 
variety of human diseases can be studied (4).
In the coming years, crucial themes for moving the field of epidemiology forward will 
include sharing of resources, data, and metadata; evaluation of new methods and 
technologies to measure exposures, susceptibility, and outcomes; and identification of new 
ways of collecting personal (e.g., mobile health or “m-health”) and macro-level data. Shared 
resources such as whole genome sequencing of study participants will help in epidemiologic 
studies across age and disease spectra.
The use and evaluation of new methods and technologies in epidemiologic research, 
including new methods of data collection, require extra attention. For example, in the 
rapidly moving field of genomics and other “omics,” editors of this Journal have anticipated 
the need for education and information dissemination about various omics fields in the 
Practice of Epidemiology section (5). A few Primers on -Omic Technologies have been 
published in the past year (6–10), and more are under way.
More generally, we need to rethink workforce development and training of 21st century 
epidemiologists in data sciences, collaborative research, and more. This sentiment was 
echoed in a recent collaborative paper from the American College of Epidemiology on the 
need to retool epidemiologic competencies in the coming decades to ensure relevance of the 
field and enhance its ability to adapt to evolving global health needs (11).
At the heart of the transformation of epidemiology is perhaps a revised expectation of what 
the field can or cannot deliver even in the midst of a technological revolution. Undoubtedly, 
large-scale population studies tend to be expensive, and the integration of additional 
measurements will make them even more expensive. Vasan and Folsom commented on, 
among other things, the undue focus of the National Heart, Lung, and Blood Institute report 
on administrative efficiency and cost savings (12). In addition, the focus on the value of 
risk-factor epidemiology, which has been debated for years, is put into sharper focus in the 
era of precision medicine. As commented by Keyes and Galea, a focus on “precision” in risk 
factor analysis “could come at the expense of engagement with the broader causal 
architecture that produces population health” (13, p. 305). Integrating social and biological 
determinants in epidemiologic studies is easy in principle but difficult to achieve. Kuller et 
al. echoed some of the same sentiments and further criticized the development of “large 
mega cohorts without attention to specific hypotheses” (14, p. 1350). Clearly, 
epidemiologists have a vested interest in making the field more “consequentialist” (15) and 
“translational” (16). The epidemiology community will need to shape the evolution of the 
field and ultimately “what will truly matter most for changing population health” (13, p. 
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310). We also need to assess how to leverage existing epidemiology resources and develop 
new studies to improve human health. We invite readers of the Journal to take a look at 
some of the issues listed in Table 1, consider others that might be important, and join in the 
conversation about the future of epidemiology by submitting commentaries or letters for 
publications in the Journal.
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Thematic Areas, Recommendations, and Selected Issues for Discussion in Planning for the Future of 
Epidemiology
Recommendation Themes National Heart, Lung, and Blood Institute (3) National Cancer Institute (4) Selected Issues for Discussion
Scientific direction Convene a scientific forum to 
anticipate the major scientific 
questions and methodological 
needs in epidemiology and 
population science over the next 
10–20 years.
Transform the practice and 
extend the reach of 
epidemiology beyond initial 
discovery to include more 
translation, evaluation, and 
implementation.
How can we integrate multiple 
determinants of population health, 
including biological, social, and 
environmental factors?
How can we encourage academic 
and research institutions to 
promote career advancement that 
rewards interdisciplinary and 
translational research?
Resource sharing Create a dynamic compendium of 
large epidemiologic resources, 
including cohort studies, data sets 
from clinical trials, registries, 
biorepositories, and other relevant 
epidemiologic resources to assist 
the research community in 
identifying and accessing key 
existing resources and to improve 
the return on the investment from 
these studies.
Provide greater access to data, 
metadata, and specimens to 
foster collaboration, to ensure 
reproducibility and replication, 
and to accelerate translation into 
policies that impact population 
health.
How can we support the 
harmonization and quality of 
existing epidemiologic data 
(including cohorts and consortia) 
and the creation of new population 
study repositories?
Should all new observational 
epidemiologic studies be registered 
(like randomized controlled trials)?
How can we develop incentives for 
data sharing and for 
reproducibility and replication?
Maximization of the research 
potential of existing cohorts
Create a cohort consortium to 
support large-scale collaborations 
and provide a coordinated, 
interdisciplinary approach to 
address scientific questions, 
achieve economies of scale, create 
opportunities for collaboration, 
and accelerate the pace of research 
and the implementation of new 
methods.
Expand cohort studies across the 
lifespan and include multiple 
health outcomes. Maximize the 
output and productivity from 
existing cohorts and assess the 
need for new cohorts of etiology 
and outcomes, including 
multiple health-related outcomes 
and intermediate biomarkers.
How can a cohort consortium 
provide a collaborative platform 
for implementation of large scale 
multioutcome initiatives (such as 
the Precision Medicine Initiative)?
Methods and technologies Actively engage in studies to 
establish the validity, reliability, 
and scalability of electronic tools 
for primary data collection.
Develop and validate reliable 
methods and technologies to 
quantify exposures and 
outcomes in massive scale and 
to assess concomitantly multiple 
factors in complex diseases.
How can epidemiology play a role 
in validating and integrating new 
methods and technologies?
Training and workforce 
development
Establish an adequate workforce to 
conduct population sciences “of 
the future”; one approach is to 
create multifaceted and 
complementary career 
development grants.
Train 21st century 
epidemiologists with an 
increasing emphasis on 
collaboration, multilevel 
analyses, data science, 
knowledge integration, and 
translation.
What new competencies are 
needed for 21st century 
epidemiologists to address 
emerging scientific questions and 
global health issues?
Integration of observational 
and interventional 
epidemiology
Where genuine efficiencies can be 
created, encourage the integration 
of clinical trials and epidemiologic 
studies.
Foster integration of 
observational epidemiologic 
studies with intervention trials.
How can we encourage more 
“experimentation” in large-scale 
epidemiologic cohort studies?
Evaluation and return on 
investment
Implement a competitive peer 
review–based model for its 
portfolio of large epidemiologic 
and population studies.
Support knowledge integration 
and meta research (systematic 
reviews, modeling, decision 
analysis, etc.) to identify gaps, 
inform funding, and integrate 
epidemiologic knowledge into 
decision making.
Is planning for the future of 
epidemiology too narrowly 
focused on administrative 
efficiency and resource saving?
Develop and design rational 
cost-effective epidemiologic 
studies and resources to optimize 
funding, accelerate translation, 
and maximize health impact.
Can metrics be developed for 
evaluating the success and impact 
of epidemiologic research?
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